Treating ATTR-CM With a Novel Therapeutic Approach: Understanding the ATTRibutes to Success - a podcast by ReachMD

CME credits: 0.25

Valid until: 11-12-2024

Claim your CME credit at https://reachmd.com/programs/cme/treating-attr-cm-with-a-novel-therapeutic-approach-understanding-the-attributes-to-success/16201/

Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This is partly due to our better understanding of the biology of the disease and recognition of its comorbid or co-occurring conditions in both cardiac and noncardiac patients with cardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, provide an updated review of the disease state that includes a better understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and examine evidence from clinical trials that are impacting the evolving landscape.

=

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD